Crohn's & Colitis Foundation
Kate Hassey has a diverse and extensive work experience spanning different roles and industries. Kate is currently the Senior Director of Digital Strategy at the Crohn's & Colitis Foundation since 2022. Prior to that, they worked at the Massachusetts Institute of Technology from 2019-2022, first as a Digital Strategist and then as an Associate Director of Digital Marketing. Kate also has experience as a Marketing Consultant and Strategist at Kate Hassey Marketing since 2013, providing digital marketing services to established brands and start-ups. Kate has held leadership positions such as Director of Marketing at Gutenberg Technology from 2017-2019 and Marketing Director at Storyboard That from 2015-2017. Kate has also worked as a Digital Marketing Consultant at Bausch + Lomb, an Adjunct Professor at the University of New Hampshire, a Digital Marketing Strategist at Hay Creek Hotels, and a Marketing Director at ANVIL ENTERTAINMENT RECORDERS. Lastly, they briefly served as a Marketing Director at Epsen Fuller Group. Overall, Kate Hassey has a strong background in digital marketing, strategy, and leadership.
Kate Hassey earned a Bachelor's degree in Communication from the University of New Hampshire between 1999 and 2003. Kate then pursued further education and completed a Certificate program in Wine Studies at Boston University in 2007. Later, from 2008 to 2010, Kate attended Suffolk University - Sawyer Business School, where they obtained their MBA with a specialization in Marketing. The information does not provide details about any education beyond these mentioned experiences. Additionally, there is a mention of "BG" in the education history, but no further information is provided regarding the specific institution or degree obtained.
This person is not in any teams
Crohn's & Colitis Foundation
5 followers
The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD). The Foundation’s mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life for the millions of Americans living with IBD. Our work is dramatically accelerating the research process through our database and investment initiatives; we also provide extensive educational resources for patients and their families, medical professionals, and the public.